Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination
Alex Dulovic
1, Monika Strengert
1, Gema Morillas Ramos
1, Matthias Becker, Johanna Griesbaum, Daniel Junker, Karsten Lürken, Andrea Beigel, Eike Wrenger, Gerhard Lonnemann, Anne Cossmann, Metodi V. Stankov, Alexandra Dopfer-Jablonka, Philipp D. Kaiser, Bjoern Traenkle, Ulrich Rothbauer, Gérard Krause
2![Comments to Author](/eid/content/images/icon/email.gif)
, Nicole Schneiderhan-Marra
2![Comments to Author](/eid/content/images/icon/email.gif)
, and Georg M.N. Behrens
2
Author affiliations: University of Tübingen Natural and Medical Sciences Institute, Reutlingen, Germany (A. Dulovic, M. Becker, J. Griesbaum, D. Junker, P.D. Kaiser, B. Traenkle, U. Rothbauer, N. Schneiderhan-Marra); Helmholtz Centre for Infection Research, Braunschweig, Germany (M. Strengert, G. Krause); TWINCORE GmbH Centre for Experimental and Clinical Infection Research, Hannover, Germany (M. Strengert, G. Krause); Hannover Medical School, Hannover (G. Morillas Ramos, A. Cossmann, M.V. Stankov, A. Dopfer-Jablonka, G.M.N. Behrens); Dialysis Centre Eickenhof, Langenhagen, Germany (K. Lürken, A. Beigel, E. Wrenger, G. Lonnemann); German Centre for Infection Research, Hannover–Braunschweig, Germany (A. Dopfer-Jablonka, G. Krause, G.M.N. Behrens); University of Tübingen Pharmaceutical Biotechnology, Tübingen (U. Rothbauer); Centre for Individualized Infection Medicine, Hannover (G.M.N. Behrens)
Main Article
Figure 2
![Reduced neutralizing capacity against SARS-CoV-2 variants of concern observed in a study of immune response against variants of concern in dialysis patients 4 months after SARS-CoV-2 mRNA vaccination. Neutralizing capacity of plasma IgG toward SARS-CoV-2 variants of concern Alpha (A), Beta (B), and Gamma and Delta (C) in the dialysis (blue circles, n = 76) and control (red circles, n = 23) groups 16 weeks after second vaccination with Pfizer-BioNTech vaccine BNT162b2 (https://www.pfizer.com). Neutralization capacity is displayed as ratio, where 1 indicates maximum neutralization and 0 no neutralization. Horizontal lines within boxes indicate medians; box tops and bottoms indicate the 25th and 75th percentiles; whiskers show the largest and smallest nonoutlier values. Outliers were determined by 1.5 times interquartile range. Statistical significance was calculated by 2-sided Mann–Whitney–U test. ACE2, angiotensin-converting enzyme 2; NS, not significant; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; T1, timepoint 1; T2, timepoint 2.](/eid/images/21-1907-F2.jpg)
Figure 2. Reduced neutralizing capacity against SARS-CoV-2 variants of concern observed in a study of immune response against variants of concern in dialysis patients 4 months after SARS-CoV-2 mRNA vaccination. Neutralizing capacity of plasma IgG toward SARS-CoV-2 variants of concern Alpha (A), Beta (B), and Gamma and Delta (C) in the dialysis (blue circles, n = 76) and control (red circles, n = 23) groups 16 weeks after second vaccination with Pfizer-BioNTech vaccine BNT162b2 (https://www.pfizer.com). Neutralization capacity is displayed as ratio, where 1 indicates maximum neutralization and 0 no neutralization. Horizontal lines within boxes indicate medians; box tops and bottoms indicate the 25th and 75th percentiles; whiskers show the largest and smallest nonoutlier values. Outliers were determined by 1.5 times interquartile range. Statistical significance was calculated by 2-sided Mann–Whitney–U test. ACE2, angiotensin-converting enzyme 2; NS, not significant; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; T1, timepoint 1; T2, timepoint 2.
Main Article
Page created: December 28, 2021
Page updated: March 19, 2022
Page reviewed: March 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.